Cantor Fitzgerald Has Positive View of ABEO FY2025 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Abeona Therapeutics in a research note issued to investors on Wednesday, April 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will earn ($1.17) per share for the year, up from their previous forecast of ($1.44). The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share.

Several other analysts also recently commented on ABEO. Oppenheimer began coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price for the company. HC Wainwright raised their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, April 30th. Finally, StockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 24th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Abeona Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $18.75.

Abeona Therapeutics Trading Down 6.8 %

Abeona Therapeutics stock traded down $0.39 during trading hours on Friday, reaching $5.37. 842,969 shares of the company's stock were exchanged, compared to its average volume of 566,495. The firm has a market capitalization of $261.96 million, a PE ratio of -1.99 and a beta of 1.68. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm's 50 day simple moving average is $5.12 and its 200 day simple moving average is $5.60. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.19.

Insider Transactions at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares in the company, valued at $6,478,439.16. This trade represents a 1.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors have recently added to or reduced their stakes in ABEO. Wellington Management Group LLP bought a new position in shares of Abeona Therapeutics during the fourth quarter valued at about $520,000. Trexquant Investment LP purchased a new stake in Abeona Therapeutics in the 4th quarter worth approximately $382,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the third quarter worth $84,000. JPMorgan Chase & Co. grew its holdings in shares of Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock worth $424,000 after acquiring an additional 28,606 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company's stock valued at $2,942,000 after buying an additional 83,050 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.